Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Early assessment of abuse potential.

Sygnature offers a range of models that can be used to explore the pharmacological profiles of novel drugs compared to known drugs of abuse, allowing the early assessment of abuse potential.

Locomotor activity

All drugs of abuse will either increase or decrease locomotor activity in rodents. While this assessment is vulnerable to false positives (i.e. many drugs which affect locomotor activity are not abused) a negative finding in this model can provide reassurance that a drug does not possess abuse potential.

In-vivo microdialysis

In-vivo microdialysis can be used to show the effect of drugs of abuse on extracellular dopamine levels in the rat nucleus accumbens. Many drugs of abuse share this effect, providing a useful and cost-effective screening tool for the early assessment of abuse potential.

Ex-vivo receptor binding

Ex vivo binding can be used to determine occupancy of the test drug at abuse-related receptors, binding sites and transporters in the brain.

  • Our receptor binding services include off-the-shelf assays for well-characterised neurotransmitter receptors and uptake sites using commercially available [3H] radioligands
  • We use high speed quantitative autoradiography using the Biospace BetaIMAGERTM system
  • The data shown here demonstrate Mu and Kappa opioid receptor occupancy for morphine and pentazocine, respectively

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.